12:00 AM
 | 
Sep 10, 2007
 |  BioCentury  |  Product Development

Isentress vs. Selzentry

Isentress vs. Selzentry

Isentress raltegravir
Trial Dosing Efficacy data
Ph III (018 and 019), n=699 treatment- experienced 400 mg bid, combo w/OBT HIV RNA <50 copies/mL: 61.3% vs. 34.6% for placebo at 16 wks; 62.6% vs. 33.3% at 24 wks HIV RNA <400 copies/mL: 76.8% vs. 41.8% for placebo at 16 wks; 75.5% vs. 39.3% at 24 wks CD4 count: increased by 83.9 vs. 35.6 cells/mm3 for placebo at 16 wks; 89.2 vs. 35...

Read the full 400 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >